Artbio Raises Oversubscribed And Upsized $90 Million Series A Financing To Progress Pipeline And Isotope Technology Development For New Class Of Alpha Radioligand Therapies
Artbio Raises Oversubscribed And Upsized $90 Million Series A Financing To Progress Pipeline And Isotope Technology Development For New Class Of Alpha Radioligand Therapies
12/07/23, 12:01 PM
Location
cambridgeMoney raised
$90 million
Industry
biotechnology
Round Type
series a
Investors
Omega Funds, F Prime Capital, Third Rock Ventures
ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), today announced the closing of an oversubscribed and upsized $90 million Series A financing co-led by Third Rock Ventures and an undisclosed healthcare fund. Additionally, seed lead investors F-Prime Capital and Omega Funds participated substantially. The company's prior seed investment round of $23 million was announced in June 2023.
Company Info
Location
cambridge, massachusetts, united states
Additional Info
ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.